The US military kicked in $17m to support the Phase III development of AcelRx Pharmaceuticals Inc.'s ARX-04 and the most recently reported data for the fast-acting pain drug seem to show that it could meet the specialty customer's needs for the product.
The military did not require a single-arm, open-label clinical trial in the emergency room setting, but study is the closest...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?